{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T02:33:02Z","timestamp":1792290782304,"version":"4.4.0"},"reference-count":41,"publisher":"SAGE Publications","issue":"10","license":[{"start":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T00:00:00Z","timestamp":1674432000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>This article reviews the published data encompassing the development, pharmacology, efficacy, and safety of brincidofovir, a nucleotide analogue DNA polymerase inhibitor developed for the treatment of smallpox.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Sources:<\/jats:title>\n                    <jats:p>A literature review was conducted in PubMed, MEDLINE, and Clinicaltrials.gov from inception up to December 2022, using terms Tembexa, brincidofovir, CMX001, smallpox treatment, and variola treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Selection and Data Extraction:<\/jats:title>\n                    <jats:p>Data were limited to studies published in English language, which evaluated the efficacy and safety of brincidofovir.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Synthesis:<\/jats:title>\n                    <jats:p>Two surrogate animal models were included in the Food and Drug Administration\u2019s (FDA) decision to approve brincidofovir: ectromelia virus in mice and rabbitpox in rabbits. Phases 2 and 3 studies established safety for approval. Brincidofovir biweekly for the treatment of disseminated adenovirus disease resulted in all-cause mortality, ranging from 13.8% to 29%. In a study for cytomegalovirus prophylaxis, patients with clinically significant cytomegalovirus infection through week 24 posttransplant was 51.2% with brincidofovir and 52.3% with placebo.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Brincidofovir adds a second oral agent to treat smallpox, with a different mechanism of action than tecovirimat. In the event of a smallpox outbreak, prompt treatment will be necessary to contain its spread. Brincidofovir shows efficacy in surrogate animal models. In healthy volunteers and individuals treated, or used as prophylaxis, for cytomegalovirus or adenovirus, the primary adverse events were gastrointestinal in addition to transient hepatotoxicity. Additionally, excessive deaths were observed in hematopoietic cell transplant patients receiving it as cytomegalovirus prophylaxis, requiring a black box warning.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10600280231151751","type":"journal-article","created":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T04:54:57Z","timestamp":1674449697000},"page":"1198-1206","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":22,"title":["Brincidofovir: A Novel Agent for the Treatment of Smallpox"],"prefix":"10.1177","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0860-2108","authenticated-orcid":false,"given":"Jessica","family":"Huston","sequence":"first","affiliation":[{"name":"Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Jacksonville, FL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacey","family":"Curtis","sequence":"additional","affiliation":[{"name":"Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Jacksonville, FL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8890-938X","authenticated-orcid":false,"given":"Eric F.","family":"Egelund","sequence":"additional","affiliation":[{"name":"Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Jacksonville, FL USA"},{"name":"Infectious Disease Pharmacokinetics Laboratory, Gainesville, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2023,1,23]]},"reference":[{"key":"bibr1-10600280231151751","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiaa588"},{"key":"bibr2-10600280231151751","doi-asserted-by":"publisher","DOI":"10.32607\/20758251-2017-9-4-4-12"},{"key":"bibr3-10600280231151751","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0188453"},{"key":"bibr4-10600280231151751","doi-asserted-by":"publisher","DOI":"10.1093\/milmed\/usaa084"},{"key":"bibr5-10600280231151751","doi-asserted-by":"publisher","DOI":"10.3390\/v9110320"},{"key":"bibr6-10600280231151751","unstructured":"US Department of Health & Human Services. CBRN MCM dashboard. Published 2021. Accessed December 16, 2022. https:\/\/www.medicalcountermeasures.gov\/barda\/cbrn\/smallpox"},{"key":"bibr7-10600280231151751","unstructured":"US Department of Health and Human Services and Center for Drug Evaluation and Research. November 2019. Accessed September 28, 2022. Smallpox (variola virus) infection: developing drugs for treatment or prevention: guidance for industry. https:\/\/www.fda.gov\/media\/132623\/download"},{"key":"bibr8-10600280231151751","unstructured":"Centers for Disease Control and Prevention. Use of vaccinia virus smallpox vaccine in laboratory and health care personnel at risk for occupational exposure to orthopoxviruses\u2014recommendations of the Advisory Committee on Immunization Practices (ACIP), 2015. Published 2017. Accessed January 7, 2023. https:\/\/www.cdc.gov\/mmwr\/volumes\/65\/wr\/mm6510a2.htm?s_cid=mm6510a2_w"},{"key":"bibr9-10600280231151751","unstructured":"CDER drug and biologic animal rule approvals. Date unknown. Accessed January 7, 2023. https:\/\/www.fda.gov\/media\/150191\/download"},{"key":"bibr10-10600280231151751","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1705688"},{"key":"bibr11-10600280231151751","unstructured":"Tembexa\u00ae (Brincidofovir) [package insert]. Tredegar: Penn Pharmaceutical Services, Ltd.; 2022. Accessed December 19, 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/214460s000,214461s000lbl.pdf"},{"key":"bibr12-10600280231151751","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01683-19"},{"key":"bibr13-10600280231151751","doi-asserted-by":"publisher","DOI":"10.3390\/v2112409"},{"key":"bibr14-10600280231151751","doi-asserted-by":"publisher","DOI":"10.3390\/v2122803"},{"key":"bibr15-10600280231151751","doi-asserted-by":"publisher","DOI":"10.1038\/nrd1877"},{"key":"bibr16-10600280231151751","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0000000000000353"},{"key":"bibr17-10600280231151751","doi-asserted-by":"publisher","DOI":"10.1177\/135965350501000110"},{"key":"bibr18-10600280231151751","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000005226"},{"key":"bibr19-10600280231151751","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02814-14"},{"key":"bibr20-10600280231151751","unstructured":"Huggins JW, Baker RO, Beadle JR, Hostetler KY. Orally active ether lipid prodrugs of cidofovir for the treatment of smallpox. 2002;53:A66."},{"key":"bibr21-10600280231151751","doi-asserted-by":"publisher","DOI":"10.3390\/v2122740"},{"key":"bibr22-10600280231151751","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2007.08.003"},{"key":"bibr23-10600280231151751","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00423-07"},{"key":"bibr24-10600280231151751","doi-asserted-by":"publisher","DOI":"10.3390\/v3020063"},{"key":"bibr25-10600280231151751","doi-asserted-by":"publisher","DOI":"10.3390\/v3010047"},{"key":"bibr26-10600280231151751","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2015.02.00727"},{"key":"bibr27-10600280231151751","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2017.04.002"},{"key":"bibr28-10600280231151751","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.03340-14"},{"key":"bibr29-10600280231151751","unstructured":"Center for Drug Evaluation and Research. Pharmacology\/toxicology NDA assessment and evaluation. Date unknown. Accessed December 6, 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2021\/214460Orig1s000,%20214461Orig1s000PharmR.pdf"},{"key":"bibr30-10600280231151751","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2017.01.009"},{"key":"bibr31-10600280231151751","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05983-11"},{"key":"bibr32-10600280231151751","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2016.12.621"},{"key":"bibr33-10600280231151751","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-201407151-00329"},{"key":"bibr34-10600280231151751","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1303688"},{"key":"bibr35-10600280231151751","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.09.038"},{"key":"bibr36-10600280231151751","unstructured":"ClinicalTrials.gov. Study to assess the safety and efficacy of brincidofovir in treatment of early versus late adenovirus infection. Date unknown. Accessed December 4, 2022. https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT02087306?term=brincidofovir&phase=2&draw=2&rank=1"},{"key":"bibr37-10600280231151751","unstructured":"ClinicalTrials.gov. Study to assess brincidofovir treatment of serious diseases or conditions caused by double-stranded DNA viruses. Date unknown. Accessed December 13, 2022. https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT01143181?term=brincidofovir&phase=2&draw=2&rank=2"},{"key":"bibr38-10600280231151751","unstructured":"TPOXX\u00ae (tecovirimat) [package insert]. Winchester, KY: Catalent Pharma Solutions; 2022. Accessed December 16, 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/214518s000lbl.pdf"},{"key":"bibr39-10600280231151751","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2021.105182"},{"issue":"3","key":"bibr40-10600280231151751","first-page":"397","volume":"15","author":"Fenner F.","year":"1993","journal-title":"Hist Philos Life Sci"},{"key":"bibr41-10600280231151751","unstructured":"Centers for Disease Control and Prevention. Guidance for tecovirimat use under expanded access investigational new drug protocol during 2022 U.S. monkeypox outbreak. Published 2022. Accessed January 7, 2022. Retrieved December 8, 2022. https:\/\/www.cdc.gov\/poxvirus\/monkeypox\/clinicians\/Tecovirimat.html"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280231151751","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10600280231151751","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280231151751","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:13:02Z","timestamp":1777374782000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10600280231151751"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,23]]},"references-count":41,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["10.1177\/10600280231151751"],"URL":"https:\/\/doi.org\/10.1177\/10600280231151751","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,23]]}}}